| Literature DB >> 35347318 |
Nicola Wanner1, Geoffroy Andrieux2, Pau Badia-I-Mompel3, Carolin Edler4, Susanne Pfefferle5, Maja T Lindenmeyer1, Christian Schmidt-Lauber1, Jan Czogalla1, Milagros N Wong1, Yusuke Okabayashi1, Fabian Braun1, Marc Lütgehetmann5, Elisabeth Meister1, Shun Lu1, Maria L M Noriega6, Thomas Günther7, Adam Grundhoff7, Nicole Fischer5, Hanna Bräuninger8,9, Diana Lindner8,9, Dirk Westermann8,9, Fabian Haas1, Kevin Roedl10, Stefan Kluge10, Marylyn M Addo11,12, Samuel Huber11, Ansgar W Lohse11, Jochen Reiser13, Benjamin Ondruschka4, Jan P Sperhake4, Julio Saez-Rodriguez3, Melanie Boerries2,14, Salim S Hayek15, Martin Aepfelbacher5, Pietro Scaturro7, Victor G Puelles16, Tobias B Huber17.
Abstract
Extrapulmonary manifestations of COVID-19 have gained attention due to their links to clinical outcomes and their potential long-term sequelae1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) displays tropism towards several organs, including the heart and kidney. Whether it also directly affects the liver has been debated2,3. Here we provide clinical, histopathological, molecular and bioinformatic evidence for the hepatic tropism of SARS-CoV-2. We find that liver injury, indicated by a high frequency of abnormal liver function tests, is a common clinical feature of COVID-19 in two independent cohorts of patients with COVID-19 requiring hospitalization. Using autopsy samples obtained from a third patient cohort, we provide multiple levels of evidence for SARS-CoV-2 liver tropism, including viral RNA detection in 69% of autopsy liver specimens, and successful isolation of infectious SARS-CoV-2 from liver tissue postmortem. Furthermore, we identify transcription-, proteomic- and transcription factor-based activity profiles in hepatic autopsy samples, revealing similarities to the signatures associated with multiple other viral infections of the human liver. Together, we provide a comprehensive multimodal analysis of SARS-CoV-2 liver tropism, which increases our understanding of the molecular consequences of severe COVID-19 and could be useful for the identification of organ-specific pharmacological targets.Entities:
Mesh:
Year: 2022 PMID: 35347318 PMCID: PMC8964418 DOI: 10.1038/s42255-022-00552-6
Source DB: PubMed Journal: Nat Metab ISSN: 2522-5812